Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran for Hereditary Angioedema
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran in Patients with Hereditary Angioedema
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Heliostar Metals to Present at the Precious Metals & Critical Minerals Virtual Investor Conference October 14
